ArticleNews reportPHN-05452026-11-02 01:13 CT

GLP-1 Therapies Not Linked to Fracture Risk in Three Studies

Source · Medscape

TLDR

Medscape reports that three studies presented at the ASBMR 2026 Annual Meeting found no overall increase in fracture risk linked to GLP-1 or related therapies. Researchers reported lower fracture risk in some groups of postmenopausal women, but the meta-analysis rated the evidence as low to very low certainty.

01—Key points

01In women with type 2 diabetes, semaglutide and tirzepatide were linked to fewer fractures than some, but not all, comparison drugs.
02In postmenopausal women without diabetes, semaglutide was associated with fewer hip and forearm fractures than no semaglutide use.
03The meta-analysis found no significant overall increase in fracture risk; possible differences related to greater weight loss remain preliminary.

Why it matters Editorial

These findings address bone-safety questions surrounding GLP-1 therapies, while the reported evidence leaves uncertainty about their effects on fracture risk.

Read the original at Medscape↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.